Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
Conditions
Interventions
CX-4945
Cisplatin
+1 more
Locations
16
United States
Mayo Clinic
Scottsdale, Arizona, United States
University of Colorado- Denver
Aurora, Colorado, United States
Mayo Clinic
Jacksonville, Florida, United States
Mayo Clinic
Rochester, Minnesota, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Texas Oncology-Tyler
Tyler, Texas, United States
Start Date
June 1, 2014
Primary Completion Date
November 6, 2020
Completion Date
August 5, 2021
Last Updated
October 22, 2021
NCT07282912
NCT07146646
NCT04753996
NCT05430698
NCT06313203
NCT04421820
Lead Sponsor
Senhwa Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions